Viewing Study NCT06101134


Ignite Creation Date: 2025-12-25 @ 2:37 AM
Ignite Modification Date: 2025-12-26 @ 1:15 AM
Study NCT ID: NCT06101134
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-04-14
First Post: 2023-10-20
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Sponsor: Bristol-Myers Squibb
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module